B2M and Alzheimer disease: Subsequently, the team found that β2M levels were significantly upregulated in the brains of AD patients and bound to Aβ to form a β2M-Aβ copolymer, exacerbating its neurotoxicity, while knockdown of β2M almost antagonised the neurotoxicity of Aβ58.